Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026

Key Takeaways SNY beats Q4 earnings estimates. Net sales rose 7% but narrowly missed consensus.Sanofi's Dupixent sales jumped 32.2%, driven by strong prescriptions across indicationsSNY guided high single-digit sales growth in 2026, with earnings growing faster than sales.Sanofi (SNY) reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a reported basis and 26.7% on a constant ...